Theranos

Theranos (/ˈθɛrənoʊs/) was a privately held health technology corporation.[2] It was initially touted as a breakthrough technology company, with claims of having devised blood tests that needed only very small amounts of blood and could be performed very rapidly using small automated devices the company had developed. However, the claims later proved to be false.[3][4][5] Founded in 2003 by then-19-year-old Elizabeth Holmes,[6] Theranos raised more than US$700 million from venture capitalists and private investors,[7] resulting in a $10 billion valuation at its peak in 2013 and 2014.[8][9] Theranos was hyped to its investors and in the media as a breakthrough in the blood-testing market, where the U.S. diagnostic-lab industry posts annual sales of over $70 billion. Theranos claimed its technology was revolutionary and that its tests required only about 1/100 to 1/1,000 of the amount of blood that would ordinarily be needed and cost far less than existing tests. https://en.wikipedia.org/wiki/Theranos

earlyish investors

• 2004 Seed $0.5M DFJ (Tim Draper)
• 2005 Series A $5.8M Rupert Murdoch
• 2006 Series B $9.1M ATA Ventures
• 2006 Series C $28.5M Larry Ellison, ATA Ventures
• 2010 Venture round $45M